# US 2021/0071200 A1 · Delivery across cell plasma membranes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071200 A1
- Document ID: US20210071200A1
- Status: Published application
- Kind: A1
- Application number: 17/092,161
- Filed: 2020-11-06
- Published: 2021-03-11
- Earliest claimed: 2014-10-24
- Assignees: Avectas Limited
- Applicants: Avectas Limited
- Inventors: Michael Maguire; Shirley O'Dea
- Web page: https://patentgrep.com/patent/US20210071200A1

## CPC

- C12N 15/895: {using biolistic methods}
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 31/721: Dextrans
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B05B 1/02: designed to produce a jet, spray, or other discharge of particular shape or nature, e.g. in single drops, {or having an outlet of particular shape}(B05B1/26, B05B1/28, B05B1/34 take precedence)
- B05B 7/2491: {characterised by the means for producing or supplying the atomising fluid, e.g. air hoses, air pumps, gas containers, compressors, fans, ventilators, their drives}
- C12M 25/14: {Scaffolds; Matrices (in general C12N5/0068)}
- C12M 33/04: {by injection or suction, e.g. using pipettes, syringes, needles (pipettes in general B01L3/02)}
- C12M 35/04: {Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli}
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0656: {Adult fibroblasts}
- C12N 5/0662: {Stem cells}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2500/12: Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N 2500/30: Organic components
- C12N 2500/34: Sugars
- C12N 2500/60: Buffer, e.g. pH regulation, osmotic pressure
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B05B: SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES (spray-mixers with nozzles B01F25/72; processes for applying liquids or other fluent materials to surfaces by spraying B05D)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Delivering a payload across a plasma membrane of a cell includes providing a population of cells and contacting the population of cells with a volume of an aqueous solution. The aqueous solution includes the payload and alcohol content greater than 5 percent concentration. The volume of the aqueous solution may be a function of exposed surface area of the population of cells, or may be a function of a number of cells in the population of cells. Related compositions, apparatus, systems, techniques, and articles are also described.

## Claims

### Claim 1

A method for delivering a payload across a plasma membrane of a cell, comprising:
providing a population of cells; and
contacting the population of cells with a volume of aqueous solution, the aqueous solution including the payload and an alcohol at greater than 2 percent concentration,
wherein the volume is a function of: (i) exposed surface area of the population of cells; or (ii) a number of cells in the population of cells;
wherein the population of cells comprises non-adherent cells, and the non-adherent cells include at least one of primary or immortalized hematopoietic stem cell (HSC), T cells, natural killer (NK) cells, cytokine-induced killer (CIK) cells, human cord blood CD34+ cells, B cells, or induced pluripotent stem cells.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the volume is
(a) between 6.0×10−7 microliter per cell and 7.4×10−4 microliter per cell;
(b) between 9.3×10−6 microliter per cell and 2.8×10−5 microliter per cell;
(c) between 4.9×10−6 microliter per cell and 2.2×10−3 microliter per cell;
(d) about 1.9×10−5 microliters per cell, wherein about is within 10 percent;
(e) between 2.6×10−9 microliter per square micrometer of exposed surface area and 1.1×10−6 microliter per square micrometer of exposed surface area;
(f) between 5.3×10−8 microliter per square micrometer of exposed surface area and 1.6×10−7 microliter per square micrometer of exposed surface area; or
(g) about 1.1×10−7 microliter per square micrometer of exposed surface area, wherein about is within 10 percent.

### Claim at position 4

-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein (a) a total volume of aqueous solution of 20 μl is delivered to a cell-occupied area of about 1.9 cm2, wherein about is within 10 percent or (b) a total volume of aqueous solution of 10 μl is delivered to a cell-occupied area of about 0.95 cm2, wherein about is within 10 percent.

### Claim at position 6

-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein said aqueous solution comprises an ethanol concentration of 5 to 30%.

### Claim 23 (depends on 1)

The method of claim 1, wherein said aqueous solution comprises one or more of 75 to 98% H2O, 2 to 45% ethanol, 6 to 91 mM sucrose, 2 to 35 mM potassium chloride, 2 to 35 mM ammonium acetate, and 1 to 14 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES).

### Claim at position 9

-28. (canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein the payload comprises a small chemical molecule, a peptide or protein, or a nucleic acid.

### Claim 30 (depends on 29)

The method of claim 29, wherein
(a) the small chemical molecule comprises a molecular mass of less than 1,000 Da;
(b) the small chemical molecule comprises a molecular mass of less than 1,000 Da, and wherein the small chemical molecule comprises MitoTracker® Red CMXRos, propidium iodide, methotrexate, or DAPI (4′,6-diamidino-2-phenylindole);
(c) the peptide comprises ecallantide, liraglutide, or icatibant;
(d) the nucleic acid comprises a small-interfering RNA (siRNA);
(e) the nucleic acid comprises a small-interfering RNA (siRNA), and wherein the siRNA molecule comprises a molecular mass of about 15,000 Da;
(f) the protein comprises a molecular mass about 1,000-150,000 Da;
(g) the protein comprises an antibody, or fragment thereof;
(h) the protein comprises an antibody, or fragment thereof, and wherein the antibody or fragment thereof comprises an anti-actin antibody, an anti-GAPDH antibody, an anti-Src antibody, an anti-Myc ab, and an anti-Raf antibody; or
(i) the nucleic acid molecule comprises greater than 5,000,000 Da.

### Claim at position 12

-38. (canceled)

### Claim 39 (depends on 1)

The method of claim 1, wherein the payload comprises a therapeutic agent, a diagnostic agent, a fluorescent molecule, or a detectable nanoparticle.

### Claim 40 (depends on 39)

The method of claim 39, wherein (a) the therapeutic agent includes at least one of cisplatin, aspirin, a statin, and fluoxetine; (b) the diagnostic agent includes at least one of methylene blue, patent blue V, and indocyanine green; or (c) the nanoparticle comprises a quantum dot.

### Claim at position 15

-45. (canceled)

### Claim 46 (depends on 1)

The method of claim 1, wherein the population of cells is substantially confluent, wherein substantially is greater than 75 percent confluent.

### Claim 47 (depends on 1)

The method of claim 1, wherein the population of cells form a monolayer of cells.

### Claim at position 18

-99. (canceled)

### Claim 100 (depends on 1)

The method of claim 1, wherein the population of cells comprises macrophages.

### Claim 101 (depends on 1)

The method of claim 1, wherein the population of cells comprises mesenchymal stem cells.

### Claim 102 (depends on 1)

The method of claim 1, wherein the payload comprises nucleic acid.

### Claim 103 (depends on 1)

The method of claim 1, wherein the payload comprises mRNA.

### Claim 104 (depends on 1)

The method of claim 1, wherein the aqueous solution includes the alcohol at greater than 5 percent concentration.

### Claim 105 (depends on 1)

The method of claim 1, wherein said aqueous solution comprises an ethanol concentration of 2 to 30%.

### Claim 106 (depends on 1)

The method of claim 1, wherein the volume of aqueous solution is delivered to the population of cells in the form of a spray.

### Claim 107 (depends on 106)

The method of claim 106, wherein the spray comprises a colloidal or sub-particle comprising a diameter of 1 nm to 100 μm.

### Claim 108 (depends on 1)

The method of claim 1, wherein the population of cells is in contact with said aqueous solution for 0.1-10 minutes prior to adding a second volume of buffer or culture medium to submerse or suspend said population of cells.

### Claim 109 (depends on 108)

The method of claim 108, wherein the buffer or culture medium comprises a second aqueous solution.

### Claim 110 (depends on 109)

The method of claim 109, wherein the second aqueous solution comprises saline.

### Claim 111 (depends on 110)

The method of claim 110, wherein the saline comprises phosphate buffered saline (PBS).

### Claim 112

A method for delivering a payload across a plasma membrane of a cell, comprising:
providing a population of cells; and
contacting the population of cells with a volume of aqueous solution, the aqueous solution including the payload and an alcohol at greater than 2 percent concentration,
wherein the volume is a function of: (i) exposed surface area of the population of cells; or (ii) a number of cells in the population of cells;
wherein the population of cells comprises adherent cells, and the adherent cells include at least one of primary or immortalized mesenchymal stem cells, lung cells, neuronal cells, fibroblasts, human umbilical vein (HUVEC) cells, and human embryonic kidney (HEK) cells.

### Claim 113 (depends on 112)

The method of claim 112, wherein the population of cells is in contact with said aqueous solution for 0.1-10 minutes prior to adding a second volume of buffer or culture medium to submerse or suspend said population of cells.

### Claim 114 (depends on 112)

The method of claim 112, wherein said aqueous solution comprises an ethanol concentration of 5 to 30%.

### Claim 115

A method for delivering a payload across a plasma membrane of a cell, comprising:
providing a population of cells; and
contacting the population of cells with a volume of aqueous solution, the aqueous solution including the payload and an alcohol at greater than 2 percent concentration,
wherein the volume is a function of: (i) exposed surface area of the population of cells; or (ii) a number of cells in the population of cells;
wherein the population of cells is in contact with said aqueous solution for 0.1 10 minutes prior to adding a second volume of buffer or culture medium to submerse or suspend said population of cells; and wherein the buffer or culture medium comprises a second aqueous solution.

### Claim 116 (depends on 115)

The method of claim 115, wherein the population of cells comprises adherent cells, and the adherent cells include at least one of primary or immortalized mesenchymal stem cells, lung cells, neuronal cells, fibroblasts, human umbilical vein (HUVEC) cells, or human embryonic kidney (HEK) cells.

### Claim 117 (depends on 115)

The method of claim 115, wherein the population of cells comprises non-adherent cells, and the non-adherent cells include at least one of primary or immortalized hematopoietic stem cell (HSC), T cells, natural killer (NK) cells, cytokine-induced killer (CIK) cells, human cord blood CD34+ cells, or B cells.

### Claim 118 (depends on 115)

The method of claim 115, wherein said aqueous solution comprises an ethanol concentration of 5 to 30%.
